Benatar, Michael http://orcid.org/0000-0003-4241-5135
Wuu, Joanne http://orcid.org/0009-0005-9643-9855
Huey, Edward D.
McMillan, Corey T.
Petersen, Ronald C.
Postuma, Ronald
McHutchison, Caroline
Dratch, Laynie http://orcid.org/0000-0002-2179-3199
Arias, Jalayne J.
Crawley, Anita
Houlden, Henry http://orcid.org/0000-0002-2866-7777
McDermott, Michael P.
Cai, Xueya
Thakur, Neil http://orcid.org/0000-0003-2099-3364
Boxer, Adam http://orcid.org/0000-0002-1215-5064
Rosen, Howard
Boeve, Bradley F. http://orcid.org/0000-0002-4153-8187
Dacks, Penny
Cosentino, Stephanie
Abrahams, Sharon
Shneider, Neil http://orcid.org/0000-0002-3223-7366
Lingor, Paul http://orcid.org/0000-0001-9362-7096
Shefner, Jeremy
Andersen, Peter M. http://orcid.org/0000-0003-0094-5429
Al-Chalabi, Ammar http://orcid.org/0000-0002-4924-7712
Turner, Martin R. http://orcid.org/0000-0003-0267-3180
Petersen, Ronald C.
Allred, Peggy
Appel, Stanley
Benatar, David
Berry, James
Bradbury, Meg
Bruijn, Lucie
Buczyner, Jennifer
Carberry, Nathan
Caress, James
Champney, Thomas
Dave, Kuldip
Fradette, Stephanie
Granit, Volkan
Grignon, Anne-Laure
Gubitz, Amelie
Harms, Matthew
Heiman-Patterson, Terry
Hesterlee, Sharon
Lawrence, Karen
Lewis, Travis
Levy, Oren
Mozaffar, Tahseen
Stanislaw, Christine
Thompson, Alexander
Uspenskaya, Olga
Weydt, Patrick
Zinman, Lorne
,
Article History
Accepted: 3 April 2024
First Online: 20 May 2024
Change Date: 29 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41582-024-00978-4
Competing interests
: M.B. receives consulting fees for Alector, Alexion, Annexon, Arrowhead, Biogen, Cartesian, Denali, Eli Lilly, Horizon, Immunovant, Novartis, Roche, Sanofi, Takeda, UCB and UniQure. The University of Miami has licensed intellectual property to Biogen to support design of the ATLAS study. R.C.P. reports consulting for Roche, Genentech, Eli Lilly and Co., Eisai, and Nestle. R.P. reports grants and personal fees from Fonds de la Recherche en Sante, grants from the Canadian Institute of Health Research, the Michael J. Fox Foundation, the National Institute of Health, Roche and the Webster Foundation, and personal fees from Takeda, Abbvie, Biogen, Bristol Myers Squibb, Curasen, Eisai, the International Parkinson and Movement Disorders Society, Korro, Lilly, Merck, Novartis, Paladin, Parkinson Canada, and Vaxxinity outside the submitted work. L.D. reports consulting for Biogen, MJH Life Sciences, Passage Bio and Sano Genetics. N.T. is an employee of the ALS Association. A.B. has served as a paid consultant to AGTC, Alector, Alzprotect, Amylyx, Arkuda, Arrowhead, Arvinas, Aviado, Boehringer Ingelheim, Denali, Eli Lilly, GSK, Humana, Life Edit, Merck, Modalis, Oligomerix, Oscotec, Roche, Transposon and Wave. B.F.B. reports honoraria for scientific advisory board activities for the Tau Consortium, funded by the Rainwater Charitable Foundation, and institutional research grant support for clinical trials from Alector, Biogen, Cognition Therapeutics, EIP Pharma, GE Healthcare and Transposon. P.D. is an employee of Association for Frontotemporal Degeneration. P.L. reports honoraria for advisory boards, consultancies or speaker remuneration from Abbvie, Alexion, Bial, Desitin, ITF Pharma, Novartis Pharma, Stada Pharm, Woolsey Pharma and Zambon. He is a co-inventor on patents EP 2825175 B1, US 9.980,972 B2 for the treatment of ALS. His work on ALS is funded by the Bundesministerium für Bildung und Forschung (01ED2204A, 01GM1917A, 01GM1704A/B), the Deutsche Forschungsgemeinschaft (SyNergy project-ID 390857198) and the Deutsche Gesellschaft für Muskelkranke (DGM). P.M.A. reports paid consultancies and serves/has served on advisory boards for Arrowhead, Avrion, Biogen, Orphazyme, Regeneron, Roche, and uniQure and as clinical trial site investigator for AB Science, Alexion Pharmaceuticals, AL-S Pharma and Lilly, Amylyx, Biogen Idec, IONIS Pharmaceuticals, Orion Pharma, Rhône-Poulenc and Sanofi. Since 1993, he has been Director of the ALS-genetic laboratory at Umeå University Hospital, which performs not-for-profit research genetic testing. He is a member of the ClinGen ALS Gene variant Curation Expert panel. A.A.-C. reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm, Cytokinetics, GenieUs, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, Orion Pharma, Quralis, Sano, Sanofi and Wave Pharmaceuticals, and the following patent: “Use of CSF-Neurofilament determinations and CSF-Neurofilament thresholds of prognostic and stratification value with regards to response to therapy in neuromuscular and neurodegenerative diseases”. The other authors report no conflicts of interest.